SDC1 and androgen insensitivity syndrome: This finding suggests a trend favoring the adoption of a bridging treatment strategy in the SWIFT DIRECT trial, despite previous research indicating that elevated peripheral blood syndecan-1 levels could predict poor outcomes in AIS patients undergoing thrombolytic therapy (28).